David S Maxwell
Affiliations: | 1995-1997 | Chemistry | DuPont-Merck Pharmaceutical Company |
| 1997-2003 | Chemistry | Encysive Pharmaceuticals | |
| 2003-2004 | Chemistry | Rice University, Houston, TX | |
| 2004-2008 | Experimental Diagnostic Imaging | The University of Texas M D Anderson Cancer Center, USA | |
| 2008-2014 | Experimental Therapeutics | The University of Texas M D Anderson Cancer Center, USA | |
| 2014- | Enterprise Data Engineering & Analytics | The University of Texas M D Anderson Cancer Center, USA |
Area:
Computational Chemistry, Data ScienceWebsite:
http://www.linkedin.com/in/david-maxwell-16999713Google:
"David Maxwell"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin YH, Satani N, Hammoudi N, et al. (2020) Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism |
| Lin YH, Satani N, Hammoudi N, et al. (2020) An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nature Metabolism |
| Lin Y, Satani N, Hammoudi N, et al. (2017) Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer Molecular Cancer Therapeutics. 16 |
| Leonard PG, Satani N, Maxwell D, et al. (2016) SF2312 is a natural phosphonate inhibitor of enolase. Nature Chemical Biology |
| Lin Y, Satani N, Hammoudi N, et al. (2016) POMHEX, a cell-permeable enolase inhibitor for collateral lethality targeting of ENO1-deleted glioblastoma European Journal of Cancer. 69: S124 |
| Lin Y, Marszalek J, Sun Y, et al. (2015) Abstract C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity Molecular Cancer Therapeutics. 14 |
| Peng Z, Maxwell D, Sun D, et al. (2014) Design and Synthesis of an Inositol Phosphate Analog Based on Computational Docking Studies. Tetrahedron. 70: 984-990 |
| Peng Z, Maxwell DS, Sun D, et al. (2014) Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). Bioorganic & Medicinal Chemistry. 22: 1450-8 |
| Peng Z, Maxwell DS, Sun D, et al. (2014) Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level. Bioorganic & Medicinal Chemistry. 22: 623-32 |
| Zuo M, Maxwell D, Prasad BAB, et al. (2014) Abstract 5361: Development of targeted inhibitors against RecQ1 helicase Cancer Research. 74: 5361-5361 |